The CLEAR (Considering Leading Experts’ Antithrombotic Regimes around peripheral angioplasty) survey: an international perspective on antiplatelet and anticoagulant practice for peripheral arterial endovascular intervention

KHF Wong; DC Bosanquet; GK Ambler; MI Qureshi; RJ Hinchliffe; CP Twine; A Betanco; A Mingoli; A Isaak; A Holden; A Tambyraja; A Argyriou; AD Godfrey; A Hassouna; A Diamantopoulos; A Saratzis; A Sharif; A Awopetu; B Gwilym; C Eng; C Maturi; C Senaratne; C Graham; C Oliver; C Raphael; CL Espada; E Kavanagh; E Klenk; E Beropoulis; E Martinez; E Mpaili; F Verzini; F Gallardo; G Piffaretti; G Celoria; Gladiol; GP Tapia; G Saggu; H Travers; J Gordon-Smith; J Kirk; J Olivier; J Chuen; J Buxton; J Hamid; J Quarmby; J Nicholls; K Stavroulakis; L Drudi; MV Usai; M Rotger; M Gawenda; M Ionac; M Almuhdhafer; NJ Jie; N Troisi; N Dattani; N Patelis; P Sapienza; P Sirignano; P Lapolla; R Nijjer; R Rajagopal; R Farraresi; R Biagioni; R Pancharatnam; S Bahia; S Sica; S Spiliopoulos; S Fazzini; T Moledina; T Akhtar; T Aherne; T Broszey; T Moloney

Journal article

The CLEAR (Considering Leading Experts’ Antithrombotic Regimes around peripheral angioplasty) survey: an international perspective on antiplatelet and anticoagulant practice for peripheral arterial endovascular intervention

KHF Wong, DC Bosanquet, GK Ambler, MI Qureshi, RJ Hinchliffe, CP Twine, A Betanco, A Mingoli, A Isaak, A Holden, A Tambyraja, A Argyriou, AD Godfrey, A Hassouna, A Diamantopoulos, A Saratzis, A Sharif, A Awopetu, B Gwilym, C Eng Show all

Cvir Endovascular | SPRINGERNATURE | Published : 2019

DOI: 10.1186/s42155-019-0079-8

Download PDF

Abstract

Background: Antiplatelet and anticoagulant therapy are commonly used before, during and after peripheral arterial endovascular intervention. This survey aimed to establish antiplatelet and anticoagulant choice for peripheral arterial endovascular intervention in contemporary clinical practice. Methods: Pilot-tested questionnaire distributed via collaborative research networks. Results: One hundred and sixty-two complete responses were collected from responders in 22 countries, predominantly the UK (48%) and the rest of the European Union (44%). Antiplatelet monotherapy was the most common choice pre-procedurally (62%). In the UK, there was no difference between dual and single antiplatelet t..

View full abstract

University of Melbourne Researchers

Jason Chuen Author

Grants

Funding Acknowledgements

GA, MQ and RH were supported by the NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol. CT was supported by Research and Development at North Bristol NHS trust.